Simonas Simonelis

## gist:60a02c662a9ae15ba41da57c354ab405
**September 26 2025 Close – Harrow, Inc. Analyst/Investor Day – Transcript (condensed)**
*(Each original paragraph retained; wording tightened, no numbers removed.)*

---

**Michael Biega**

Good morning. Welcome to Harrow’s first Investor & Analyst Day. I’m Mike Biega, VP Investor Relations & Comms. Today’s remarks may contain forward-looking statements – see our latest 10-K and 10-Qs for risks.

Forward-looking statements involve many uncertainties beyond Harrow’s control, including commercialization of FDA-approved and compounded products and timing of FDA decisions on candidates. See “Risk Factors.”
	September 26 2025 Close – Harrow, Inc. Analyst/Investor Day – Transcript (condensed)
	(Each original paragraph retained; wording tightened, no numbers removed.)

	---

	Michael Biega

	Good morning. Welcome to Harrow’s first Investor & Analyst Day. I’m Mike Biega, VP Investor Relations & Comms. Today’s remarks may contain forward-looking statements – see our latest 10-K and 10-Qs for risks.

	Forward-looking statements involve many uncertainties beyond Harrow’s control, including commercialization of FDA-approved and compounded products and timing of FDA decisions on candidates. See “Risk Factors.”